Aberrant EZHIP expression drives tumorigenesis in osteosarcoma

Area of Science:

• Oncology
• Epigenetics
• Molecular Biology

Background:

• Osteosarcomas (OS) are aggressive bone cancers with complex genetic alterations.
• Recurrent oncogenic driver mutations are rare in OS, necessitating the identification of alternative pathogenic mechanisms.

Purpose of the Study:

• To investigate the role of EZHIP (enhancer of zeste homolog 2-interacting protein) in osteosarcoma pathogenesis.
• To determine if EZHIP expression correlates with patient outcomes and response to therapy.

Main Methods:

• Analysis of EZHIP expression in two independent osteosarcoma patient cohorts.
• Gain- and loss-of-function experiments to assess EZHIP's oncogenic activity in vitro and in vivo.
• Evaluation of H3K27me3 deposition and its correlation with therapeutic response and patient prognosis.

Main Results:

• Ectopic EZHIP expression was identified in 20% of osteosarcoma patients.
• Reduced H3K27me3 levels, associated with EZHIP, correlated with poor histological response to neoadjuvant therapy and worse patient outcomes.
• EZHIP promoted OS aggressiveness by reprogramming epigenetic marks, reactivating developmental pathways, and impairing mesenchymal progenitor differentiation towards non-smooth muscle lineages.

Conclusions:

• EZHIP is a prevalent driver in osteosarcomas, contributing to tumor aggression and poor prognosis.
• EZHIP-mediated epigenetic alterations impede normal cell differentiation, favoring a more aggressive tumor phenotype.
• Targeting EZH2 in EZHIP-expressing osteosarcomas may represent a potential therapeutic strategy.